BUY

Choice

Integrating Design & Engineering; Ramp up in Al-led investments

Tata Elxsi reported Q4FY24 revenues at INR9,059mn (-0.6% QoQ and +7.2% YoY in CC terms), de-grew 0.9% sequentially but grew 8.1% YoY. For FY24, it delivered a growth of 9.6% YoY in cc terms and 13% YoY to INR35.5bn despite global macroeconomic uncertainties and volatility in the media and communications industry over the last few quarters. The reported PAT for full year stood at INR7.9bn (+4.9% YoY) representing a net margin of 22.3%. EPS for the year stood at INR127.2.

- Outlook for FY25E: The management has laid down a strategy of integrating its design business deeply with its key industry verticals, complementing their software and digital business with a design-led proposition. This will enhance its competitive differentiation, provide early visibility into customer product roadmaps, and create larger downstream development deals. Under Transportation segment, management is confident of maintaining its growth trajectory from the SDV programs of 5 global OEMs. Under Healthcare segment, company has established a strong foundation for continued growth with the addition of five market customer logos in the year and expanded capabilities and platforms in new growth areas such as digital therapeutics and connected health. It is making strategic investments and securing contracts for GenAI-driven solutions tailored for the healthcare sector. Management is quite bullish and expects Healthcare segment to lead the organization for next few quarters. Media and Communication segment seems to have bottomed out and is expected to witness recovery from FY25E. There are opportunities in contributing to the revenues through advertising technologies and enabling optics reductions to automation and transformation of network operations. SIS business is pivoting to value-added services, innovation-led projects such as experience centres, and supporting downstream deployment and run management for its products and platforms. Company expects FY25E to be better than FY24.
- GenAl ready: On the Al and Gen Al front, company continues to invest strongly in solutions, POCs and projects and ramp up the talent across the company. It has created and deployed specialized programs to be able to get 25% of its engineers Al-ready by Q3FY25E. Company is working on experimenting and innovating using GenAI across design and software. It is targeting areas that may be impacted by GenAI in the business, such as coding, automated testing, that is being proactively taken to customers.
- EBITDA Margins to improve: EBITDA margins for Q4FY24 came at 28.8%, down 70bps QoQ and 100bps YoY due to high training cost in investment capability building. Company aspires to be in the similar range as FY23 with huge headspace in utilization level improvement. Company saw a net addition of 178 new employees in Q4, contributing to a total of 1,535 new Elxsians in FY24 with attrition levels at 12.4%. Looking ahead, the company plans to on-board approximately 1,500 to 2,000 fresh engineers in FY25E depending on demand.

Valuation: The management is committed to growth backed by strategic relationships built over the years with key customers, the qualitative change in revenues towards OEMs and SDV programs, entries into new operators and marquee healthcare logos, investments and talents in hiring, investments in strategic technology areas in AI and a strong deal pipeline We maintain our rating to BUY with a revised target price of INR8,095 implying a PE of 45x on FY26E EPS of INR180.

Financial Snapshot

Year end: March	FY22	FY23	FY24	FY25E	FY26E
Revenue (INR Mn.)	24,708	31,447	35,521	39,742	46,582
Gross Profit (INR Mn.)	10,565	13,607	14,471	16,663	19,904
EBIT (INR Mn.)	7,104	8,799	9,472	10,885	13,036
EBIT Margin (%)	28.8	28.0	26.7	27.4	28.0
EPS (INR)	88.3	121.3	127.2	150.5	179.9

Source: Company, CEBPL

Apr 24, 2024

CMP (Rs.)	7,394
Target Price (Rs.)	8,095
Potential Upside (%)	9.5

Company Info

company mic	
BB Code	TELX IN EQUITY
ISIN	INE670A01012
Face Value (Rs.)	10.0
52 Week High (Rs.)	9,191.1
52 Week Low (Rs.)	6,217.9
Mkt Cap (Rs. bn.)	460.5
Mkt Cap (\$ bn.)	5.5
Shares o/s (Mn.)/Float	62.3/56
FY24 EPS (Rs.)	127.2
FY26E EPS (Rs.)	179.9

Shareholding Pattern (%)

	Mar-24	Dec-23	Sep-23
Promoters	43.92	43.92	43.92
FII's	14.56	15.02	13.80
DII's	6.06	5.71	4.81
Public	35.46	35.35	37.47

Relative Performance (%)

YTD	3Y	2Y	1Y
BSE IT	31.3	5.5	29.3
Tata Elxsi	131.6	(11.5)	17.5

Rebased Price Performance



CA Vatsal Vinchhi, Analyst

Email: vatsal.vinchhi@choiceindia.com Ph: +91 22 6707 9224

Ashutosh Murarka, Associate

Email: ashutosh.murarka@choiceindia.com Ph: +91 22 6707 9442

Sequential Operating Performance

	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24
Income Statement						
Revenues (INR Mn.)	8,177	8,379	8,503	8,817	9,142	9,059
Gross Profit (INR mn.)	3,579	3,529	3,497	3,547	3,739	3,688
Gross Margin (%)	43.8	42.1	41.1	40.2	40.9	40.7
EBIT (INR mn.)	2,254	2,287	2,301	2,388	2,447	2,337
EBIT Margin (%)	27.6	27.3	27.1	27.1	26.8	25.8
PAT (INR mn.)	1,947	2,016	1,889	2,002	2,064	1,969
Basic EPS (INR)	31.3	32.4	30.3	32.2	33.2	31.6
Operating Metrics						
Revenue - Geography (%)						
Americas	42.8	41.4	40.2	39.6	37.4	36.0
Europe	34.7	35.5	37.4	40.0	40.5	40.3
India	16.2	17.3	17.0	15.5	16.4	17.3
RoW	6.3	5.8	5.3	4.9	5.7	6.4
Total	100.0	100.0	99.9	100.0	100.0	100.0
Revenue - Segments (%)						
Embedded Product Design	85.9	85.8	85.9	86.0	86.0	-
Industrial Design & Visualization	11.4	11.3	11.3	11.3	11.3	-
Software and Design Service	-	-	-	-	-	97.2
System Integration & Support	2.7	2.9	2.8	2.7	2.7	2.8
Total	100.0	100.0	100.0	100.0	100.0	100.0
EPD Revenue - Industry (%)						
Transportation	44.3	44.6	44.8	46.2	46.5	51.4
Media & Communications	40.3	40.3	39.8	38.4	37.8	33.6
Healthcare & Medical Devices	15.4	15.1	15.4	15.4	15.7	14.1
Others	-	-	-	-	-	0.9
Total	100.0	100.0	100.0	100.0	100.0	100.0
EPD Revenue - Contract Type (%)						
Time & Material	49.9	49.6	48.4	49.7	50.0	52.1
Fixed Price	50.1	50.4	51.6	50.3	50.0	47.9
Total	100.0	100.0	100.0	100.0	100.0	100.0
EPD Revenue - Effort Mix (%)						
Onsite	24.6	25.5	25.3	25.8	25.3	26.3
Offshore	75.4	74.5	74.7	74.2	74.7	73.7
Total	100.0	100.0	100.0	100.0	100.0	100.0
Employee Metrics						
Total Headcount	11,607	11,864	12,286	12,871	13,221	13,399
Attrition Rate LTM (%)	18.4	17.3	15.6	13.7	12.9	12.4

Source: Company, CEBPL

CEBPL Estimates vs Actual for Q4FY24

Tata Elxsi (INR Mn.)	Q4FY24	Q4FY23	YoY(%)	Q3FY24	QoQ (%)	CEBPL Est.	Dev. (%)
Revenues	9,059	8,379	8.1	9,142	(0.9)	9,447	(4.1)
Employee Cost	5,371	4,850	10.7	5,403	(0.6)		
Gross Profit (INR mn.)	3,688	3,529	4.5	3,739	(1.4)	3,828	(3.7)
Gross Margin (%)	40.7	42.1	(140) bps	40.9	(19) bps	40.5	19 bps
Other costs	1075	1031	4.3	1038	3.6		
Depreciation	276	211	30.9	255	8.4		
EBIT (INR mn.)	2,337	2,287	2.2	2,447	(4.5)	2,507	(6.8)
EBIT Margin (%)	25.8	27.3	(149) bps	26.8	(97) bps	26.5	(74) bps
Other Income	337	257	31.2	349	(3.6)		
Interest	50	41	20.9	56	(10.5)		
PBT (INR mn.)	2624	2502	4.9	2741	(4.3)		
Tax	655	487	34.5	676	(3.2)		
Adj. PAT (INR mn.)	1,969	2,016	(2.3)	2,064	(4.6)	2,114	(6.8)
Basic EPS (INR)	31.6	32.4	(2.3)	33.2	(4.6)	33.9	(6.8)

Source: Company, CEBPL

Change in estimates

Income Statement		FY25E		FY26E			
(INR Mn.)	Old	New	Dev. (%)	Old	New	Dev. (%)	
Revenues	41,842	39,742	(5.0)	49,810	46,582	(6.5)	
Gross Profit	17,545	16,663	(5.0)	21,389	19,904	(6.9)	
Gross Profit Margin (%)	41.9	41.9	(0) bps	42.9	42.7	(21) bps	
EBIT	11,624	10,885	(6.4)	14,329	13,036	(9.0)	
EBIT Margin (%)	27.8	27.4	(39) bps	28.8	28.0	(78) bps	
EPS	160.8	150.5	(6.4)	197.6	179.9	(9.0)	


Source: Company, CEBPL

Historical 1 Yr Fwd PE Band




Source: Company, CEBPL

Decline in Revenue in Q4




Source: Company, CEBPL

Industry Vertical Revenue Mix




Source: Company, CEBPL

Attrition rate on a declining trend; Net hiring improved



Source: Company, CEBPL

Margins to improve



Source: Company, CEBPL

Management Call - Highlights

- The Board of Directors has proposed a final dividend of INR70 per equity share for the fiscal year ending on March 31st, 2024, pending approval by the shareholders.
- During the financial year, the transportation business experienced robust growth, expanding by 20.5% YoY in cc terms. Presently, it represents nearly half of its total SDS revenues. Within this segment, the services for OEMs constitute more than 56% of the transportation business and have become integral to the SDV programs of five major global OEMs.
- During the quarter, Tata Elxsi secured a significant deal in the rail sector driven by digital technology. This deal involves the development of an advanced collision detection and warning system for a rail operator based in North America.
- In the healthcare and life sciences sector, the business achieved a YoY growth of 7.6% in cc terms for the financial year. Tata Elxsi laid a solid groundwork for sustained expansion by acquiring five new major customer partnerships during the year. Additionally, they broadened its capabilities and platforms in emerging growth areas like digital therapeutics and connected health.
- Tata Elxsi is making strategic investments and securing contracts for Gen-Aldriven solutions tailored for the healthcare sector. This includes pioneering initiatives such as identifying and removing harmful substances from the medical device supply chain. Furthermore, the company is actively developing platforms and clinching agreements for digital therapeutics, showcasing its commitment to advancing healthcare through innovative technology solutions.
- In the media and communication business, there was a decline of 2.6% in constant cc terms over the financial year. Nevertheless, the management foresees potential opportunities to bolster revenue streams through advertising technologies (ad tech) and facilitating cost reductions via the automation and transformation of network operations.
- Tata Elxsi remains committed to strengthening its key customer relationships, as evidenced by notable growth among the top 10 and top 25 customers companywide. Additionally, the company is proactively investing in talent development, ensuring a robust talent pipeline for future needs.

Financial Summary (Consolidated in INR Mn.)

Income Statement (INR Mn.)	FY22	FY23	FY24	FY25E	FY26E
Revenue	24,708	31,447	35,521	39,742	46,582
Gross profit	10,565	13,607	14,471	16,663	19,904
EBITDA	7,657	9,613	10,467	12,133	14,594
Depreciation	553	814	994	1,248	1,558
EBIT	7,104	8,799	9,472	10,885	13,036
Other income	445	738	1,219	1,351	1,584
Interest expense	94	162	203	219	257
PAT	5,496	7,553	7,925	9,373	11,203
EPS	88.3	121.3	127.2	150.5	179.9

Balance Sheet (INR Mn.)	FY22	FY23	FY24	FY25E	FY26E
Tangible fixed assets	1,489	1,667	1,944	2,211	2,543
Goodwill & intangible assets	1,447	1,739	2,037	2,037	2,037
Investments	-	-	-	-	-
Cash & Cash equivalents	9,652	11,916	13,571	15,574	18,179
Other non-current assets	1,799	1,094	2,521	2,647	2,780
Other current assets	7,305	11,219	11,796	12,374	12,993
Total assets	21,692	27,634	31,870	34,844	38,531
Shareholder's funds	16,009	20,858	25,057	27,868	31,229
Borrowings	-	-	-	-	-
Lease liabilities	1,385	1,823	2,240	2,240	2,240
Other non-current liabilities	398	455	542	510	593
Other current liabilities	3,900	4,500	4,031	4,225	4,469
Total equity & liabilities	21,692	27,634	31,870	34,844	38,531

Cash Flows (INR Mn.)	FY22	FY23	FY24	FY25E	FY26E
Cash flows from Operations	6,893	6,717	9,592	10,979	13,527
Cash flows from Investing	(1,083)	(2,019)	(2,701)	(164)	(306)
Cash flows from financing	(3,261)	(3,031)	(4,278)	(6,780)	(8,099)

Ratio Analysis	FY22	FY23	FY24	FY25E	FY26E
Growth Ratios (%)					
Revenues	35.3	27.3	13.0	11.9	17.2
Gross Profit	47.8	28.8	6.4	15.1	19.5
EBITDA	46.6	25.5	8.9	15.9	20.3
EBIT	48.6	23.9	7.6	14.9	19.8
Margin Ratios (%)					
Gross Profit Margin	42.8	43.3	40.7	41.9	42.7
EBITDA Margin	31.0	30.6	29.5	30.5	31.3
EBIT Margin	28.8	28.0	26.7	27.4	28.0
Profitability (%)					
Return on equity	34.3	36.2	31.6	33.6	35.9
Return on invested capital	63.3	59.6	49.2	54.6	61.3
Return on capital employed	39.9	38.0	34.0	35.5	38.3
Valuation					
OCF / Net profit (%)	87.9	64.5	88.5	88.9	92.5
EV / EBITDA (x)	46.9	47.0	42.9	37.0	30.8
Book Value per share (x)	257.1	335.0	402.3	447.5	501.4
Free Cash flow yield (%)	0.8	1.1	1.4	1.6	2.1
Courses Company CERN					

Source: Company, CEBPL.

Historical recommendations and target price: TATA ELSXI Ltd.



Tat	Tata Elxsi Ltd.					
1.	21-04-2022	REDUCE,	Target Price 7,415			
2.	17-07-2022	NEUTRAL,	Target Price 8,350			
3.	17-10-2022	REDUCE,	Target Price 7,953			
4.	25-01-2023	ADD,	Target Price 7,114			
5.	20-05-2023	ADD,	Target Price 7,933			
6.	18-07-2023	ADD,	Target Price 8,100			
7.	25-09-2023	NEUTRAL,	Target Price 7,610			
8.	18-10-2023	ADD,	Target Price 8,076			
9.	24-01-2024	ADD,	Target Price 8,890			
10.	18-03-2024	BUY,	Target Price 8,890			
11.	24-04-2024	BUY,	Target Price 8,095			

Institutional Research Team						
Kripashankar Maurya	AVP - Institutional Research – Automobiles/Defence/Healthcare	kripashankar.maurya@choiceindia.com	+91 22 6707 9949			
CA Vatsal Vinchhi	Analyst - Information Technology	vatsal.vinchhi@choiceindia.com	+91 22 6767 9224			
Deepika Murarka	Analyst - Pharmaceuticals	deepika.murarka@choiceindia.com	+91 22 6707 9513			
Vijay Singh Gaur	Analyst - BFSI	vijay.gour@choiceindia.com	+91 22 6707 9422			
Ashutosh Murarka	Associate – Cement / Building Material	ashutosh.murarka@choiceindia.com	+91 22 6707 9442			
Putta Ravi Kumar	Associate - Goods & Defence	ravi.putta@choiceindia.com	+91 22 6707 9908			
Aayush saboo	Associate – Real Estate	aayush.saboo@choiceindia.com	+91 22 6707 9811			
Maitri Sheth	Associate – Pharmaceuticals	maitri.sheth@choiceindia.com	+91 22 6707 9811			
Bharat Kumar Kudikyala	Associate – Cement / Building Material	bharat.kudikyala@choiceindia.com	+91 22 6707 9798			
CA Sheetal Murarka	Vice President - Institutional Sales	sheetal.murarka@choiceindia.com	+91 22 6707 9857			
Nitesh Jalan	AVP – Institutional Sales	nitesh.jalan@choiceindia.com	+91 22 6707 9877 /878 /879			

CHOICE RATING DISTRIBUTION & METHODOLOGY

OUTPERFORM The security is expected to generate more than 25% returns over the next 12 months

BUY The security is expected to generate greater than 5% to less than 25% returns over the next 12 months

REDUCE The security expected to show downside or upside returns by 0% to 5% over the next 12 months

SELL The security expected to show Below 0% next 12 months

Disclaimer

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Choice Equity Broking Private Limited-Research Analyst - INH000000222. (CIN. NO.: U65999MH2010PTC198714). Reg. Add.: Sunil Patodia Tower, J B Nagar, Andheri(East), Mumbai 400099. Tel. No. 022-6707 9999

Compliance Officer--Prashant Salian, Email Id – Prashant.salain@choiceindia.com Contact no. 022- 67079999- Ext-2310

Grievance officer-Deepika Singhvi Tel.022-67079999- Ext-834. Email- ig@choiceindia.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

This Research Report (hereinafter referred as "Report") has been prepared by Choice Equity Broking Private Limited as a Research Entity (hereinafter referred as "CEBPL RE" Limited. The Research Analysts, strategists are principally responsible for the preparation of "CEBPL RE" research. The research analysts have received compensation based upon various factors, which may include quality of research, investor client feedback, stock picking, competitive factors and firm revenues etc.

Whilst CEBPL has taken all reasonable steps to ensure that this information is correct, CEBPL does not offer any warranty as to the accuracy or completeness of such information. Any person

placing reliance on the report to undertake trading does so entirely at his or her own risk and CEBPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.

General Disclaimer: This 'Report' is strictly meant for use by the recipient and is not for circulation. This Report does not take into account particular investment objectives, financial situations or specific needs of individual clients nor does it constitute a personal recommendation. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through CEBPL nor any solicitation or offering of any investment

/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide

for the readers. No action is solicited based upon the information provided herein. Recipients of this "Report" should rely on information/data arising out of their own Study/investigations. It is advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This 'Report' has been prepared on the basis of publicly available information, internally developed data and other sources believed by CEBPL to be reliable. CEBPL or its directors, employees, affiliates or representatives shall not be responsible for, or warrant for the accuracy, completeness, adequacy and reliability of such information / opinions / views. Though due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of CEBPL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report.

The price and value of the investments referred to in this Report and the income from them may tend to go down as well as up, and investors may incur losses on any investments. Yester performance shall not be a guide for future performance. CEBPL does not provide tax advice to its clients, and all investors are strongly advised to take advice of their tax advisers regarding

taxation aspects of any potential investment. Opinions are based on the current scenario as of the date appearing on this 'Report' only. CEBPL does not undertake to advise you as to any change of our views expressed in this "Report' may differ on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold CEBPL, its employees and associates responsible for any losses, damages of any type whatsoever.

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject "CEBPL RE" to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by "CEBPL RE" in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this 'Report' shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. "CEBPL" requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to "CEBPL". Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in Mumbai (India).

Statements on ownership and material conflicts of interest, compensation - CEBPL and Associates reciprocates to the best of the knowledge and belief of CEBPL/ its Associates/ research Analyst who is preparing this report.

Disclosures of Interest (Additional):

- 1. "CEBPL", its research Analyst(s), or its associates or relatives of the Research Analyst does not have any financial interest in the company(ies) covered in this report.
- 2. "CEBPL" its research Analyst, or its associates or relatives of the research analyst
- 3. affiliates collectively do not hold more than 1 of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
- 4. "CEBPL", its research analyst, his/her associate, his/her relative, do not have any other material conflict of interest at the time of publication of this research report.
- "CEBPL", its research analyst, and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months.
- "CEBPL", its research analyst, or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies)
 covered in
 this report.
- 7. "CEBPL, or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report.
- 8. CEBPL research analyst has not served as an Officer, Director, or employee of the company (ies) covered in the Research report.
- 9. "CEBPL", its research analyst has not been engaged in market making activity for the company(ies) covered in the Research report.

Details of Associates of CEBPL and Brief History of Disciplinary action by regulatory authorities are available on our website i.e. www. https://choiceindia.com/research-listing

The details of CEBPL, its research analyst and its associates pertaining to the companies covered in the Research report are given below

Sr. No.	Particulars	Yes / No
1.	Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for investment banking transaction by CEBPL	No
2	Whether Research Analyst, CEBPL or its associates or relatives of the Research Analyst affiliates collectively hold more than 1 of the company(ies) covered in the Research report	No
3.	Whether compensation has been received by CEBPL or its associates from the company(ies) covered in the Research report	No
4.	CEBPL or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the company(ies) covered in the Research report	No
5.	CEBPL, its research analyst, his associate, or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve months	No

Copyright: The copyright in this research report belongs exclusively to CEBPL. All rights are reserved. Any unauthorized use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the CEBPL's prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

This "Report" is for distribution only under such circumstances as may be permitted by applicable law. This "Report" has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This "Report" is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither CEBPL nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this "report" or lack of care in this report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Information barriers may be relied upon by CEBPL, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of CEBPL.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States. The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by CEBPL with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior written consent of CEBPL and CEBPL accepts no liability whatsoever for the actions of third parties in this respect.

The details of CEBPL, its research analyst and its associates pertaining to the companies covered in the Research report are given below